Share on StockTwits

Quest Diagnostics (NYSE:DGX) SVP Michael E. Prevoznik sold 14,377 shares of the stock on the open market in a transaction dated Monday, August 4th. The stock was sold at an average price of $61.01, for a total transaction of $877,140.77. Following the transaction, the senior vice president now directly owns 43,330 shares in the company, valued at approximately $2,643,563. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Quest Diagnostics (NYSE:DGX) traded down 1.29% during mid-day trading on Tuesday, hitting $60.57. 1,381,064 shares of the company’s stock traded hands. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock’s 50-day moving average is $60.06 and its 200-day moving average is $57.12. The company has a market cap of $8.747 billion and a price-to-earnings ratio of 11.53.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.08 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.06 by $0.02. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Analysts expect that Quest Diagnostics will post $4.05 EPS for the current fiscal year.

A number of research firms have recently commented on DGX. Analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday. They now have a $64.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, July 25th. They now have a $65.00 price target on the stock, up previously from $60.00. Finally, analysts at Maxim Group raised their price target on shares of Quest Diagnostics from $68.00 to $74.00 in a research note on Friday, July 25th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $61.62.

Quest Diagnostics Incorporated (NYSE:DGX) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.